CN105412129A - 一种大蒜素复合液体组合物及其应用 - Google Patents
一种大蒜素复合液体组合物及其应用 Download PDFInfo
- Publication number
- CN105412129A CN105412129A CN201510890161.7A CN201510890161A CN105412129A CN 105412129 A CN105412129 A CN 105412129A CN 201510890161 A CN201510890161 A CN 201510890161A CN 105412129 A CN105412129 A CN 105412129A
- Authority
- CN
- China
- Prior art keywords
- garlicin
- allicin
- oligochitosan
- liquid composition
- complex liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 title claims abstract description 10
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 235000010081 allicin Nutrition 0.000 title claims abstract description 10
- 239000007788 liquid Substances 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 150000001944 cysteine derivatives Chemical class 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 25
- 229920001661 Chitosan Polymers 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- 239000002131 composite material Substances 0.000 claims description 14
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 108010089807 chitosanase Proteins 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 244000245420 ail Species 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 2
- 235000019996 baijiu Nutrition 0.000 abstract 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 description 7
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 2
- 235000015295 alliin Nutrition 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 108010092760 Alliin lyase Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/105—Persulfides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药生物技术领域，涉及一种大蒜素复合液体组合物及其应用，大蒜素复合液体组合物中大蒜素含量为0.5-8％W/V，壳寡糖含量为1-10％W/V，半胱氨酸衍生物含量为0.5-8％W/V，其余为白酒，能够用于制备治疗肿瘤的药物或保健食品；其配比科学合理，原料易得，成本低，具有显著的抗肿瘤作用，其抗肿瘤作用优于单纯的大蒜素溶液，应用前景广阔。
Description
技术领域：
本发明属于医药生物技术领域，涉及一种大蒜素复合液体组合物及其应用，特别是一种大蒜素复合壳寡糖、半胱氨酸衍生物的液体组合物及其应用。
背景技术：
恶性肿瘤是危害人类健康的重大疾病，具有发病率高、治愈率低、死亡率高的特点，已成为当今重大疾病的首位。我国是一个人口大国，随着人口老龄化进程的加快，生活节奏和生活环境的改变，恶性肿瘤发病率持续上升，肿瘤防治形势非常严峻。
大蒜素是大蒜中的蒜氨酸(alliin)经蒜氨酸酶(alliinase)催化形成含烯丙基的硫代化合物，溶于水，易溶于乙醇。大蒜素是大蒜中的主要活性物质,具有广谱抗菌作用，在已报道的资料中，涉及大蒜素用作农作物抗菌抗病的复配剂、动物饲料的添加剂，以及用于保健食品中的高血脂症的调节和外用抗菌制剂等，虽然大蒜素具有一定的抗菌、抗肿瘤作用，但其抗肿瘤作用较弱；半胱氨醇与乙酰半胱氨酸是半胱氨酸化学改性的衍生物，半胱氨酸是机体生物合成蛋白质的主要组成氨基酸，在维持蛋白质的高级结构和生物学功能方面发挥着重要作用，同时具有抗氧化、清除机体自由基作用；壳寡糖是壳聚糖经酶法降解制成的低分子量寡糖，具有良好的水溶性，易于人体吸收，具有提高机体免疫力等生物学功能。目前，尚未见有将大蒜素、半胱氨酸衍生物和壳聚糖一起使用的相关报道。
发明内容：
本发明的目的在于克服现有技术存在的缺点，寻求设计提供一种大蒜素复合液体组合物及其应用，用于制备治疗肿瘤的药物或保健食品。
为了实现上述发明目的，本发明所述大蒜素复合液体组合物包括大蒜素、壳寡糖、半胱氨酸衍生物和白酒，其中大蒜素含量为0.5-8％W/V，壳寡糖含量为1-10％W/V，半胱氨酸衍生物含量为0.5-8％W/V，其余为白酒。
本发明所述大蒜素为市售商品醇提大蒜素，或者以鲜大蒜为原料，采用现有技术经捣碎、氧化和醇提制得。
本发明所述的壳寡糖以壳聚糖为原料，经壳聚糖酶水解，制成聚合度为2-10个糖单元的商品壳寡糖。
本发明所述的半胱氨酸衍生物为市售商品N-乙酰半胱氨酸和半胱氨醇中的一种或两种。
本发明所述的大蒜素复合液体组合物的制备时，以18度-60度的白酒为溶剂，加入不同质量的醇提大蒜素、壳寡糖、半胱氨酸衍生物配制而成。
本发明所述大蒜素复合液体组合物能够用于制备治疗肿瘤的药物或保健食品。
本发明所述的大蒜素复合液体组合物为浅黄棕色透明液体，有醇香和大蒜素气味。
本发明与现有技术相比，将大蒜素复合具有提高机体免疫力的壳寡糖作用、具有抗氧化作用的半胱氨酸衍生物，再加上白酒的活血、加快血液运输循环作用，使制备的液体组合物抗肿瘤作用得以加强；其配比科学合理，原料易得，成本低，具有显著的抗肿瘤作用，其抗肿瘤作用优于单纯的大蒜素溶液，应用前景广阔。
具体实施方式：
下面通过实施例对本发明作进一步说明。
实施例1：
本实施例量取60度白酒80ml，向白酒内依次加入醇提大蒜素3g、壳寡糖4g和N-乙酰半胱氨酸2g后搅拌溶解，再加53度白酒定容体积至100ml，制得含醇提大蒜素3％(W/V)、含壳寡糖4％(W/V)、含N-乙酰半胱氨酸2％(W/V)的液体组合物1。
实施例2：
本实施例量取36度白酒80ml，向白酒内依次加入醇提大蒜素1g、壳寡糖8g和N-乙酰半胱氨酸6g后搅拌溶解，再加入18度白酒定容体积至100ml，制得含醇提大蒜素1％(W/V)、含壳寡糖8％(W/V)、含N-乙酰半胱氨酸6％(W/V)的液体组合物2。
实施例3：
本实施例先量取45度白酒80ml，向白酒内依次加入醇提大蒜素8g、壳寡糖1g和半胱氨醇0.5g后搅拌溶解，再加入45度白酒定容体积至100ml，制得含醇提大蒜素8％(W/V)、含壳寡糖2％(W/V)、含半胱氨醇3％(W/V)的液体组合物3。
实施例4：
本实施例先量取36度白酒80ml，向白酒内依次加入醇提大蒜素0.5g、壳寡糖10g、N-乙酰半胱氨酸2g和半胱氨醇6g后搅拌溶解，再加入18度白酒定容体积至100ml，制得含醇提大蒜素0.5％(W/V)、含壳寡糖10％(W/V)，含N-乙酰半胱氨酸2％(W/V)、含半胱氨醇6％(W/V)的液体组合物4。
实施例5：
本实施例验证实施例1、2和4制备的液体组合物对肿瘤组织生长的抑制作用，选取实验动物为昆明种小鼠，雌雄各半，体重18～22g，复苏小鼠肝癌细胞H22，细胞常规培养后，用生理盐水调节细胞密度1.0×107/ml，以0.5ml/只的量接种于初代小鼠腹腔，接种5～7天后，进行腹腔传代，连续传3代后取腹腔传代生长良好的H22荷瘤小鼠，以颈椎脱臼法处死，再在无菌条件下抽取腹水瘤液后离心处理，用生理盐水调节细胞密度为2.0×107/ml，接种于正常小鼠左前肢腋窝皮下，每只0.2ml，制作小鼠H22荷瘤模型50只；造模24h后将50只荷瘤模型小鼠随机分为模型对照组、大蒜素对照组、实验1组、实验2和组合实验3组五组，每组10只；分别对五组模型进行以下处理：
模型对照组：对荷瘤模型小鼠给予0.2ml/20g生理盐水进行灌胃，每天1次；
大蒜素对照组：对荷瘤模型小鼠给予0.2ml/20g醇提大蒜素溶液进行灌胃，每天1次，其中醇提大蒜素溶液是将醇提大蒜素3g搅拌溶解于53度白酒并定容体积至100ml制备而成；
实验1组：对荷瘤模型小鼠给予0.2ml/20g液体组合物1进行灌胃，每天1次；
实验2组：对荷瘤模型小鼠给予0.2ml/20g液体组合物2进行灌胃，每天1次；
实验3组：对荷瘤模型小鼠给予0.2ml/20g液体组合物4进行灌胃，每天1次；
上述实验共进行12d，将小鼠在末次给药24h后脱颈椎处死，剖离瘤块，称瘤重，计算抑瘤率，实验结果如表1所示：
表1：液体组合物对肿瘤组织生长的影响
由上述实验结果可以看出，本实施例制备的大蒜素复合壳寡糖、半胱氨酸衍生物的液体组合物具有显著的抗肿瘤作用，其抗肿瘤作用优于单纯的大蒜素溶液。
Claims (5)
1.一种大蒜素复合液体组合物，其特征在于包括大蒜素、壳寡糖、半胱氨酸衍生物和白酒，其中大蒜素含量为0.5-8％W/V，壳寡糖含量为1-10％W/V，半胱氨酸衍生物含量为0.5-8％W/V，其余为白酒。
2.根据权利要求1所述大蒜素复合液体组合物，其特征在于所述大蒜素为市售商品醇提大蒜素，或是以鲜大蒜为原料，采用现有技术经捣碎、氧化和醇提制得的大蒜素。
3.根据权利要求1所述大蒜素复合液体组合物，其特征在于所述的壳寡糖以壳聚糖为原料，经壳聚糖酶水解，制成聚合度为2-10个糖单元的商品壳寡糖。
4.根据权利要求1所述大蒜素复合液体组合物，其特征在于所述的半胱氨酸衍生物为市售商品N-乙酰半胱氨酸和半胱氨醇中的一种或两种。
5.一种如权利要求1所述大蒜素复合液体组合物的应用，其特征在于用于制备治疗肿瘤的药物或保健食品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510890161.7A CN105412129A (zh) | 2015-12-04 | 2015-12-04 | 一种大蒜素复合液体组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510890161.7A CN105412129A (zh) | 2015-12-04 | 2015-12-04 | 一种大蒜素复合液体组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412129A true CN105412129A (zh) | 2016-03-23 |
Family
ID=55490980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510890161.7A Withdrawn CN105412129A (zh) | 2015-12-04 | 2015-12-04 | 一种大蒜素复合液体组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412129A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617024A (zh) * | 2016-10-17 | 2017-05-10 | 广东省阳春市信德生物科技发展有限公司 | 一种黑蒜壳寡糖口服液配方及其制备工艺 |
| CN109370851A (zh) * | 2018-11-26 | 2019-02-22 | 钟美 | 多种植物精华素酒及其制备方法 |
| CN114403181A (zh) * | 2022-01-13 | 2022-04-29 | 福气面团数字科技股份有限公司 | 抗菌添加剂、面团生产方法及零防腐剂烘焙食品 |
-
2015
- 2015-12-04 CN CN201510890161.7A patent/CN105412129A/zh not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617024A (zh) * | 2016-10-17 | 2017-05-10 | 广东省阳春市信德生物科技发展有限公司 | 一种黑蒜壳寡糖口服液配方及其制备工艺 |
| CN109370851A (zh) * | 2018-11-26 | 2019-02-22 | 钟美 | 多种植物精华素酒及其制备方法 |
| CN114403181A (zh) * | 2022-01-13 | 2022-04-29 | 福气面团数字科技股份有限公司 | 抗菌添加剂、面团生产方法及零防腐剂烘焙食品 |
| CN114403181B (zh) * | 2022-01-13 | 2023-10-27 | 福气面团数字科技股份有限公司 | 抗菌添加剂、面团生产方法及零防腐剂烘焙食品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | The antiviral activity of polysaccharides and their derivatives | |
| Murphy et al. | The potential of seaweed as a source of drugs for use in cancer chemotherapy | |
| Mao et al. | Anti-tumor and immunomodulatory activity of selenium (Se)-polysaccharide from Se-enriched Grifola frondosa | |
| CN102417544B (zh) | 一种紫阳富硒绿茶含硒多糖及其制备方法和用途 | |
| CN101626773B (zh) | 一种生体治愈促进剂 | |
| CN104352457A (zh) | 一种包含绿原酸晶型的制剂及其用途 | |
| Shin et al. | The effects of AHCC®, a standardized extract of cultured Lentinura edodes mycelia, on natural killer and T cells in health and disease: reviews on human and animal studies | |
| CN105412129A (zh) | 一种大蒜素复合液体组合物及其应用 | |
| CN105017438B (zh) | 一种白背三七多糖及其在制备用于免疫调节和抗肿瘤的药物和功能食品中的应用 | |
| CN103385976A (zh) | 普洱茶或其提取物的抗肿瘤应用 | |
| CN104799286A (zh) | 一种用于提高免疫力的组合物及其制备方法 | |
| CN105796861A (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备提高免疫功能的药物中的应用 | |
| CN104489457A (zh) | 一种用于肝癌患者的含壳寡糖蛹虫草粉的膳食配方 | |
| CN106176787A (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备抗癌或抗肿瘤药物中的应用及药物 | |
| CN104606659A (zh) | 一种抗菌、抗病毒、调节代谢、增强免疫的口服液 | |
| CN102028198B (zh) | 一种用于增强免疫力的组合物及其制备方法 | |
| CN104004110A (zh) | 一种从瓜子金中提取的瓜子金多糖及其应用 | |
| CN105902561A (zh) | 龙须菜多糖作为抗肿瘤化疗药增效剂的应用及抗肿瘤药物 | |
| CN106890140B (zh) | d-柠檬烯抗癌增效组合物及其制备方法与应用 | |
| CN105999245B (zh) | 含乌司他丁的药物组合物在制备治疗胆囊癌药物中的用途 | |
| CN101084933A (zh) | 一种增强免疫力的药物组合物及制备方法 | |
| CN105012366B (zh) | 一种明月草多糖及其在制备用于免疫调节和抗肿瘤的药物和功能食品中的应用 | |
| CN104171866A (zh) | 一种黑米皮浓缩片及其制备方法 | |
| CN104922144B (zh) | 一种具有升高白细胞作用的药物组合物及应用 | |
| TWI228991B (en) | Pharmaceuticals, foods, beverages, feeds or cosmetics inducing growth factor production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |